Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts - A Comprehensive Review

Sep 24, 2026

Human papillomaviruses (HPVs) are high-risk causative factors for HPV infection and are frequently accompanied by co-infections with other viruses. This review synthesizes recent advances in biotechnology relevant to HPV infection, emphasizing host interactions and cancerous progression. A systematic strategy compiles evidence from recent, advanced electronic sources to clarify biology, host–viral interaction cycles, cellular transformation, and malignancies linked to HPV. Emerging vaccine formats and nanotechnology-assisted drug and vaccine development are discussed, alongside the need for modern clinical screening, therapeutics, and public awareness to reduce disease burden.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Introduction

HPV subtypes and risk categories

Clinical manifestations and cancer burden

Review scope and research highlights

Host interactions and cellular transformation

Co-infections and therapeutic development

Review Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts—A Comprehensive Review Shiza Malik 1, Ranjit Sah 2, Khalid Muhammad 3 and Yasir Waheed 4,5, * Citation: Malik, S.; Sah, R.; Muhammad, K.; Waheed, Y. Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts—A Comprehensive Review. Vaccines 2023, 11, 102. [https://](https://)[ ](https://)[doi.org/10.3390/vaccines11010102](doi.org/10.3390/vaccines11010102) Academic Editor: Fabio Grizzi Received: 25 November 2022 Revised: 23 December 2022 Accepted: 26 December 2022 Published: 1 January 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Bridging Health Foundation, Rawalpindi 46000, Pakistan 2 Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu 44600, Nepal 3 Department of Biology, College of Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates 4 Ofﬁce of Research, Innovation, and Commercialization (ORIC), Shaheed Zulﬁqar Ali Bhutto Medical University, Islamabad 44000, Pakistan 5 Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon * [Correspondence: yasir_waheed_199@hotmail.com](Correspondence: yasir_waheed_199@hotmail.com) Abstract: Human papillomaviruses (HPVs) are high-risk causative factors for HPV infection. This infection does not come alone; it is often seen with co-infection with other viruses and acts as a causative agent for several malignancies. The major purpose of this comprehensive study was to highlight some recent advances in biotechnology associated with HPV infection, including understanding its host interactions and cancerous progression. A systematic research strategy was used to gather data from recent, and the most advanced published electronic sources. The compiled data explain the recent understanding of biology, host–viral interaction cycles, co-infection with other viral diseases, and cellular transformation toward malignancies associated with HPV. In recent years, some vaccination protocols have been introduced in the form of live attenuated, subunit, and DNA-based vaccines. Moreover, some strategies of nanotechnology are being employed to synthesize drugs and vaccines with a whole new approach of plant-based products. The data are immense for the proposed research question, yet the need is to implement modern follow-up screening and modern therapeutics at the clinical level and to conduct wide-scale public awareness to lessen the HPV-related disease burden. Keywords: human papillomavirus (HPV); co-infections; carcinogenesis; host-interaction; immune response; vaccines; drugs 1. Introduction Human papillomavirus (HPV) is one of the most potent viruses that cause sexually transmitted diseases in a large-scale population worldwide. Approximately 120 subtypes of HPV have been identiﬁed through various research studies, of which ~40 lead to infectious cycles in the host [1] . Some subtypes are divided into low-and high-risk HPV, depending upon the sort of disease or cancer they inﬂict on the host. Young adults are especially vulnerable to multiple strains associated with critical infection, while the risk of infection decreases with age and with the development of immunity against the virus [2] . The clinical manifestations underlying HPV infection range from benign lesions caused by low-risk oncogenic HPV (LR-HPV) to critical cancers such as head and neck, oropharyngeal, penile, vulvovaginal, anal, and, most importantly, cervical cancers caused by high-risk oncogenic HPV (HR-HPV) [3] . High-risk oncogenic HPV categories are

FAQs

What role do HPV infections play in cancer development?

HPV infection is not isolated; it often occurs with co-infections and contributes to malignant transformation. High-risk oncogenic HPV categories are linked to a significant fraction of human cancer incidences.

How does the review describe HPV biology and host interactions?

The review summarizes HPV biology, host–viral interaction cycles, and cellular transformation toward malignancies. It also outlines strategies related to understanding these processes.

Which prevention and treatment approaches are highlighted?

The review covers vaccination protocols (live attenuated, subunit, and DNA-based vaccines) and discusses nanotechnology-based approaches for drugs and vaccines. It also emphasizes the need for modern clinical screening, therapeutics, and public awareness.

Sep 24, 2026

Uploaded by RuangKosong